Brief: Formycon Confirms 2026 Guidance After H1 Revenue Rise
BRIEF-Formycon Confirms 2026 Guidance After H1 Revenue Rise Aug 12 (Reuters) - FORMYCON AG FYB.DE:
FORMYCON H1 REVENUE EUR 25.8 MILLION
FORMYCON H1 EBITDA EUR -3.4 MILLION
CONFIRMS 2026 GUIDANCE AFTER SUBSTANTIAL H1 REVENUE INCREASE
WORKING CAPITAL AT EUR 51.20 MILLION AS OF JUNE 30, 2026
H1 2026 EBITDA IMPROVES TO EUR -3.4 MILLION FROM EUR -17.9 MILLION
Source text: ID:nEQ3pQqCya
Further company coverage: FYB.DE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 587785269;))
Recent news on Formycon AG
See all newsBrief: Formycon Says Fyb286 Expands Formycon Biosimilar Pipeline Targeting Niche Indication
Brief: FORMYCON AG - ENTERS COOPERATION AGREEMENTS WITH BIOCELYS AND SANTO BIOSIMILAR FOR BIOSIMILAR CANDIDATE
Brief: Formycon And Zydus Say FYB206 Becomes First Publicly Announced Keytruda Biosimilar Accepted For Review By FDA
Brief: Formycon AG - Clinical Development Of FYB206 Completed In July 2026
Formycon H1 revenue rises sharply on milestone payments, EBITDA loss narrows